Harminder Paul
Overview
Explore the profile of Harminder Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan S, Reece D, Atenafu E, Bhella S, Chen C, Masih-Khan E, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Dec;
23(2):e97-e106.
PMID: 36564313
Background: Salvage transplant has been historically considered effective therapy for myeloma patients relapsing after first transplant, if they achieved adequate remission duration. However, the efficacy of novel agent combinations has...
2.
Lebel E, Li X, Paul H, Masih-Khan E, Bhella S, Chen C, et al.
Eur J Haematol
. 2021 Nov;
108(3):204-211.
PMID: 34767270
Objectives: The prognostic value of kinetics of response to multiple myeloma (MM) therapy is controversial. We aimed to expand the knowledge on this topic by reviewing the kinetics of response...
3.
Rivera Duarte A, Reece D, Li X, Xu W, Paul H, Masih-Khan E, et al.
Amyloid
. 2021 Sep;
29(1):23-30.
PMID: 34519603
Background: The main objective of treatment in systemic light chain amyloidosis (AL amyloidosis) is to achieve the best hematological response. Deeper responses are associated with better organ responses and survival....
4.
Lebel E, Chen C, Paul H, Trudel S, Tiedemann R
Clin Lymphoma Myeloma Leuk
. 2021 Feb;
21(6):e506-e509.
PMID: 33608216
No abstract available.
5.
Khan S, LeBlanc R, Gyger M, White D, Kaufman J, Jazubowiak A, et al.
Leuk Lymphoma
. 2021 Jan;
62(7):1721-1729.
PMID: 33509009
We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in...
6.
Chen C, Cao Y, Trudel S, Reece D, Kukreti V, Tiedemann R, et al.
Leuk Lymphoma
. 2020 Jun;
61(8):1860-1868.
PMID: 32476520
Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of...
7.
Chen C, Paul H, Snitzler S, Kakar S, Le L, Wei E, et al.
Leuk Lymphoma
. 2018 Oct;
60(4):980-989.
PMID: 30277089
Lenalidomide has anti-tumor activity in CLL but can be complicated by tumor lysis syndrome (TLS) and tumor flare (TF). In our previous study using low-dose lenalidomide in treatment-naive CLL, TLS...
8.
Chen C, Paul H, Le L, Wei E, Snitzler S, Wang T, et al.
Leuk Lymphoma
. 2018 Jun;
60(1):92-100.
PMID: 29916761
AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 trial, 30 relapsed/refractory CLL patients were treated...
9.
Chen C, Paul H, Wang T, Le L, Dave N, Kukreti V, et al.
Br J Haematol
. 2014 Mar;
165(5):731-3.
PMID: 24611934
No abstract available.
10.
Chen C, Bergsagel P, Paul H, Xu W, Lau A, Dave N, et al.
J Clin Oncol
. 2010 Dec;
29(9):1175-81.
PMID: 21189385
Purpose: Lenalidomide is an oral immunomodulatory drug with multiple effects on the immune system and tumor cell microenvironment leading to inhibition of malignant cell growth. Based on encouraging reports of...